Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives

被引:22
作者
Moreau, P
Gaillard, N
Marminon, C
Anizon, F
Dias, N
Baldeyrou, B
Bailly, C
Pierré, A
Hickman, J
Pfeiffer, B
Renard, P
Prudhomme, M [1 ]
机构
[1] Univ Clermont Ferrand, UMR 6504, F-63177 Clermont Ferrand, France
[2] IRCL, INSERM U524, F-59045 Lille, France
[3] IRCL, Lab Pharmacol Antitumorale, Ctr Oscar Lambret, F-59045 Lille, France
[4] Inst Rech Servier, Div Rech Cancerol, F-78290 Croissy Sur Seine, France
[5] Les Lab SERVIER, F-92415 Courbevoie, France
关键词
D O I
10.1016/j.bmc.2003.09.014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the course of structure-activity relationship studies, new rebeccamycin derivatives substituted in 3,9-positions on the indolocarbazole framework, and a 2,3-anhydro derivative were prepared by semi-synthesis from rebeccamycin. The antiproliferative activities against nine tumor cell lines were determined and the effect on the cell cycle of murine leukemia L1210 cells was examined. Their DNA binding properties and inhibitory properties toward topoisomerase I and three kinases PKCzeta, CDKI/cyclin B, CDK5/p25 and a phosphatase cdc25A were evaluated. The 3,9-dihydroxy derivative is the most efficient compound of this series toward CDKI/cyclin B and CDK5/p25. It is also characterized as a DNA binding topoisomerase I poison. Its broad spectrum of molecular activities likely accounts for its cytotoxic potential. This compound which displays a tumor cell line-selectivity may represent a new lead for subsequent drug design in this series of glycosylated indolocarbazoles. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4871 / 4879
页数:9
相关论文
共 34 条
[1]   Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group [J].
Anizon, F ;
Belin, L ;
Moreau, P ;
Sancelme, M ;
Voldoire, A ;
Prudhomme, M ;
Ollier, M ;
Severe, D ;
Riou, JF ;
Bailly, C ;
Fabbro, D ;
Meyer, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (21) :3456-3465
[2]   Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin [J].
Anizon, F ;
Moreau, P ;
Sancelme, M ;
Voldoire, A ;
Prudhomme, M ;
Ollier, M ;
Severe, D ;
Riou, JF ;
Bailly, C ;
Fabbro, D ;
Meyer, T ;
Aubertin, AM .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (09) :1597-1604
[3]  
Bailly C, 2001, METHOD ENZYMOL, V340, P610
[4]   Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue [J].
Bailly, C ;
Qu, XG ;
Anizon, F ;
Prudhomme, M ;
Riou, JF ;
Chaires, JB .
MOLECULAR PHARMACOLOGY, 1999, 55 (02) :377-385
[5]   The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles [J].
Bailly, C ;
Carrasco, C ;
Hamy, F ;
Vezin, H ;
Prudhomme, M ;
Saleem, A ;
Rubin, E .
BIOCHEMISTRY, 1999, 38 (27) :8605-8611
[6]  
Bailly C, 1999, CANCER RES, V59, P2853
[7]   DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin [J].
Bailly, C ;
Riou, JF ;
Colson, P ;
Houssier, C ;
RodriguesPereira, E ;
Prudhomme, M .
BIOCHEMISTRY, 1997, 36 (13) :3917-3929
[8]   Topoisomerase I poisons and suppressors as anticancer drugs [J].
Bailly, C .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (01) :39-58
[9]   SELECTIVE REDUCTION OF AROMATIC NITRO-COMPOUNDS WITH STANNOUS CHLORIDE IN NON-ACIDIC AND NON-AQUEOUS MEDIUM [J].
BELLAMY, FD ;
OU, K .
TETRAHEDRON LETTERS, 1984, 25 (08) :839-842
[10]   PRODUCTION AND BIOLOGICAL-ACTIVITY OF REBECCAMYCIN, A NOVEL ANTITUMOR AGENT [J].
BUSH, JA ;
LONG, BH ;
CATINO, JJ ;
BRADNER, WT .
JOURNAL OF ANTIBIOTICS, 1987, 40 (05) :668-678